Related Experiment Video

Updated: Jun 13, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K

EGFR-mutated NSCLC: A roadmap to treatment sequences

Nicolas Girard1

  • 1Institut Curie, Paris, France; Paris Saclay University, UVSQ, Faculté de Médecine Simone Veil, Versailles, France.

Med (New York, N.Y.)
|September 14, 2024
PubMed

Insights

The HARMONi-A trial suggests ivonescimab plus chemotherapy as a new option for non-small cell lung cancer patients who progressed after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard treatment for EGFR-mutated non-small cell lung cancer (NSCLC).
  • Acquired resistance to third-generation TKIs necessitates novel therapeutic strategies for advanced NSCLC.

Purpose of the Study:

  • To evaluate ivonescimab, a novel bispecific antibody targeting PD-1 and VEGF, in combination with chemotherapy.
  • To assess the efficacy and safety of ivonescimab plus chemotherapy as a second-line treatment for patients with EGFR-mutated NSCLC after third-generation TKI failure.

Main Methods:

  • The HARMONi-A trial is a clinical study investigating the efficacy of ivonescimab plus chemotherapy.
  • Patient population includes individuals with EGFR-mutated NSCLC who have previously received third-generation TKIs.

Main Results:

  • Recent results from the HARMONi-A trial indicate promising outcomes for the combination therapy.
  • Ivonescimab, targeting both PD-1 and VEGF, demonstrates potential as a new therapeutic approach.

Conclusions:

  • Ivonescimab plus chemotherapy represents a potential new second-line treatment option for EGFR-mutated NSCLC.
  • This combination therapy may address unmet needs in patients progressing after standard TKI treatment.

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K